• Home
  • Search Results
  • Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues.

Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues.

Cancer immunology research (2014-10-02)
Ivan Théate, Nicolas van Baren, Luc Pilotte, Pierre Moulin, Pierre Larrieu, Jean-Christophe Renauld, Caroline Hervé, Ilse Gutierrez-Roelens, Etienne Marbaix, Christine Sempoux, Benoît J Van den Eynde
ABSTRACT

Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tumoral resistance to immune rejection. In humans, constitutive expression of IDO1 has been observed in several tumor types. However, a comprehensive analysis of its expression in normal and tumor tissues is still required to anticipate the risks and potential benefits of IDO1 inhibitors. Using a newly validated monoclonal antibody to human IDO1, we performed an extensive immunohistochemical analysis of IDO1 expression in normal and tumor tissues. In normal tissues, IDO1 was expressed by endothelial cells in the placenta and lung and by epithelial cells in the female genital tract. In lymphoid tissues, IDO1 was expressed in mature dendritic cells with a phenotype (CD83(+), DC-LAMP(+), langerin(-), CD123(-), CD163(-)) distinct from plasmacytoid dendritic cells. Importantly, IDO1-expressing dendritic cells were not enriched in tumor-draining lymph nodes, in contrast with previously reported findings. IDO1-expressing cells were observed in a large fraction (505/866, 58%) of human tumors. They comprised tumor cells, endothelial cells, and stromal cells in proportions that varied depending on the tumor type. Tumors showing the highest proportions of IDO1-immunolabeled samples were carcinomas of the endometrium and cervix, followed by kidney, lung, and colon. This hierarchy of IDO1 expression was confirmed by gene expression data mined from The Cancer Genome Atlas database. Expression of IDO1 may be used to select tumors likely to benefit from targeted therapy with IDO1 inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Arginine, reagent grade, ≥98%
Sigma-Aldrich
BIS-TRIS, ≥98.0% (titration)
Sigma-Aldrich
L-Arginine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Trimesic acid, 95%
Sigma-Aldrich
Trimethylaluminum, 97%
Sigma-Aldrich
L-Arginine, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
Trimethylaluminum solution, 2.0 M in toluene
Sigma-Aldrich
L-Arginine, 99%, FCC, FG
SAFC
BIS-TRIS
SAFC
L-Arginine
Sigma-Aldrich
BIS-TRIS, BioXtra, ≥98.0% (titration)
Supelco
L-Arginine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Trimethylaluminum solution, 2.0 M in hexanes
Sigma-Aldrich
BIS-TRIS, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
Trimethylaluminum, packaged for use in deposition systems
Sigma-Aldrich
BIS-TRIS, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, ≥98.0%
Sigma-Aldrich
1-Methyl-DL-tryptophan, 97%
Sigma-Aldrich
Tris(tert-butoxy)silanol, 99.999%
SAFC
BIS-TRIS
Sigma-Aldrich
Trimethylaluminum solution, 2.0 M in heptane
Sigma-Aldrich
Tris(tert-butoxy)silanol, packaged for use in deposition systems